NeuroMedica

NeuroMedica is a clinical-stage medical device company targeting the $500M+ cerebral aneurysm treatment market with a patented flow diverter designed for bifurcation aneurysms. Its core innovation, The Backstop, is positioned as a single-device solution that avoids contact with the weakened aneurysm wall and preserves perforator vessels, potentially offering superior safety and efficacy. The company is backed by strong intellectual property from Cornell University, initial funding from the Helmsley Charitable Trust, and guided by a renowned physician advisory board. NeuroMedica is currently in the development and fundraising stage, seeking to advance its technology toward clinical trials and regulatory approval.

Patented endovascular flow diversion technology designed for deployment in the parent vessel to treat bifurcation aneurysms without contacting the aneurysm dome or occluding perforator vessels.

NeuroMedica competes in the neurovascular intervention market dominated by giants like Medtronic (Pipeline Flex, Axium coils), Stryker (Target coils, Trevo stent retrievers), and Johnson & Johnson (Cerus endovascular). Its direct competitors are other flow diversion devices (e.g., Medtronic's Pipeline) and intra-saccular flow disruptors (e.g., Stryker's WEB device). NeuroMedica's differentiation lies in its specific design for bifurcations and its claim of preserving perforator vessels, a noted limitation of some existing technologies.